Kornimate/medical-research-clean huggingface dataset:
prospective study to compare results of stn-dbs between early treated and late-treated pd patient

Conditions: Parkinson's Disease; DBS; Deep Brain Stimulation; STN

Summary: the aim of this study is to investigate the impact of dbs not only no motor outcomes, but also on neuropsychological and psychiatric aspects and on quality of life in young patients with a short history of disease.

bilateral stn dbs is a powerful treatment for advanced parkinson disease with levodopa induced motor complications. the beneficial effects of stn stimulation on motor disability and quality of life have been proved. however, the mean delay before neurosurgery is currently 14 years after diagnosis, when medical treatment no longer controls pd symptoms and quality of life is already severely impaired. aim of this study is to prospectively assess the effects of bilateral stn stimulation on motor signs, psychological and psychiatric aspects and quality of life in a group of 20 patients with pd who underwent surgery after 5 years from the onset of the disease. these results will be compared with those of a group of 20 patients with a pd history from more than 10 years. the two groups of patients will be evaluated at baseline and after 3 and 12 months from dbs implant; at each visit neurological and motor examinations were assessed and dedicated neuropsychological and psychiatric tests will be performed. neurosurgery may be considered superior to medical treatment alone even in mild to moderate pd of 10 years duration, rather than a last resort in very advanced stages of the disease. thanks to this study we could compare motor outcomes and cognitive aspects between dbs patients with a short and with long history of disease

Eligibility criteria:
inclusion criteria: * suffering from pd of \> 10 years and with lts (long term l-dopa syndrome), or with a duration of pd of 5 years * age\< 70 years * normal brain mri * absence of dementia (mini mental state examination ≥ 24) * absence of severe psychiatric diseases * signed informed consent form * absence of allergy to metal * italian native speaker * absence of communicative or perceptive deficits exclusion criteria: * any form of familiar pd * presence of neoplasia * presence of hiv * presence of severe metabolic diseases * severe cardiac/respiratory/renal or hepatic diseases * ongoing treatment with immunodepressive/ immunomodulate drugs

Keywords: parkinson dbs of stn pd deep brain stimulation of stn early treatment
clinical study on treatment of l-dopa-induced dyskinesia with tianqi pingchan granule combined with amantadine

Conditions: L-DOPA-Induced Dyskinesia

Summary: a randomized, double-blind, placebo-controlled, multi-center clinical trial was conducted to observe the improvement in the level of dyskinesia in patients with parkinson's disease during the 12-week period of oral treatment with tianqi pingchan granule combined with amantadine. to observe the differences of the safety and effectiveness between tianqi pingchan granule combined with amantadine and placebo combined with amantadine.


Eligibility criteria:
inclusion criteria: 1. pd patients between the ages of 30-85; 2. patients with parkinson's disease dyskinesia, and updrs 4.2 score ≥ 2 points; 3. the patient diary shows that there are at least two opening periods between 9 am and 4 pm every day, and the dyskinesia appears in the opening period, each time lasting more than half an hour; 4. the treatment plan for anti-parkinson's disease is stable and not adjusted within 30 days before enrollment; 5. levodopa is administered at least three times a day. exclusion criteria: 1. pd patients with biphasic, dystonia, closure, myoclonus, but no dyskinesia; 2. pregnant and lactating women; 3. taking other chinese medicines against parkinson's disease 2 weeks before enrollment; 4. impaired cognitive function (according to pre-entry mmse score): secondary education level: mmse \<24 points; primary education level \<20 points; illiterate \<17 points; 5. psychiatric symptoms associated with anti-parkinson's disease drugs 6. accompanied by a history of mental illness; 7. impaired liver and kidney function; 8. accompanied by severe other systemic diseases; 9. amantadine treatment has been received within the first 30 days of enrollment; 10. history of medication with apomorphine or dopamine receptor antagonists; 11. previously taking amantadine, unable to tolerate; 12. allergic to the amantadine, memantine, and traditional chinese medicine preparations or serious adverse reactions; 13. before the enrollment, the ekg showed obvious abnormalities and required clinical intervention. 14. has received pd-related brain surgery; 15. patients who are participating in other clinical studies or have participated in other clinical studies within the previous 30 days; 16. patients who are unable to follow up with follow-up.
yoga for fibromyalgia

Conditions: Fibromyalgia

Summary: fibromyalgia is a common, costly and debilitating illness which affects mostly women. fibromyalgia patients report widespread musculoskeletal pain, fatigue, stiffness, and distress. several consensus statements indicate that optimal care combines medication, exercise, and psychology. yoga is a popular mind/body discipline which holds promise for reducing fibromyalgia symptoms. the aim of this pilot study is to evaluate the effects of an innovative program, yoga of awareness, in which yoga poses are complemented by meditation and breathing exercises, presentations on healthy coping, and group discussions. fifty-six women with fibromyalgia will be recruited and randomly divided into two groups. one group will receive the yoga program right away, and the other group will wait 3 months before receiving the program. information about fibromyalgia symptoms and functioning will be collected from both groups before and immediately after the first group receives the yoga program. when results from the 2 groups are compared, the investigators expect patients who received the yoga program will have greater gains in fibromyalgia symptoms, physical function and pain coping capacities then those waiting to receive the program. if this study shows the yoga program is effective, the investigators will use this data in 2010 to apply to the national institutes of health for a more complete study of its benefits.


Eligibility criteria:
inclusion criteria: * women ≥21 years of age * diagnosed with fibromyalgia by acr criteria for at least 1 year * on a stable regimen of pharmacologic and/or non-pharmacologic treatment for fm ≥3 months exclusion criteria: * reside \>70 miles from the research site * unavailable to attend the intervention at one of the scheduled times * currently engaged in intensive yoga practice (practice \>3 days/wk) * score \>29 on the beck depression scale modified for fibromyalgia * currently undergoing disability application or involved in litigation * elective surgery scheduled during the study period * physically disabled in a manner that precludes meaningful participation in the intervention (eg, quadriplegic paralysis) * do not speak english
effects of cisatracurium on sccinylcholine-induced fasciculations

Conditions: Fasciculations

Summary: to investigate the effects of different doses of cisatracurium pretreatment on succinylcholine-induced fasciculations.

ninety patients scheduled for laparoscopic cholecystectomies were equally randomized into three groups to receive pretreatment of 0.005, 0.01, and 0.02 mg/kg cisatracurium, respectively. general anesthesia was induced 3.5 min later, train of four stimulation was monitored 4.5 min later, succinylcholine 1.5 mg/kg was injected 5 min later, and endotracheal intubation was implemented 6.5 min later. the side effects of cisatracurium, intensity of fasciculations, intubating conditions, time and extent to maximal depression of twitch and time for its recovery to 20% of control value, severity of myalgia at 24 h postoperatively, serum potassium before cisatracurium pretreatments, at intubating time, and 5 min after intubation were recorded.

Eligibility criteria:
inclusion criteria: * american standards association (asa) physical status i or ii patients scheduled for elective laparoscopic cholecystectomies with tracheal intubation requiring general anesthesia; * 20 - 65 years old; * without acid-base imbalance and electrolyte disturbance; * with normal hepatic and renal function. exclusion criteria: * patients with the contraindications associated with succinylcholine or cisatracurium; * patients taking drugs known to alter the action of neuromuscular blockers; * patients with a body mass index exceeding 30
effects of milking the umbilical cord on systemic blood flow

Conditions: Abnormal Vascular Flow

Summary: premature babies are at risk for bleeding in their brains, which can result in developmental delays or other neurological problems such as cerebral palsy. clamping the baby's umbilical cord immediately after birth is standard, but delaying this procedure allows more of the baby's blood to move from the placenta into the baby and prevents head bleeds. however, a delay in clamping the umbilical cord is not usually done in very premature babies, because it would delay their treatment and they could get cold. milking the umbilical cord is another way to give premature babies more of their own blood while avoiding a delay in treatment. umbilical cord milking has been shown to improve blood pressure, decrease the need for blood transfusions, and increase the amount of urine made in the first few days of life.

the aim of this study is to determine whether umbilical cord milking improves blood flow in premature babies, and thereby reduce the occurrence of neurological problems. the investigators predict that the blood flow measured by ultrasounds of the heart will be higher in babies who receive umbilical cord milking compared to those whose cords are clamped immediately. secondly, the investigators predict that cord milking will improve blood volume, blood pressure, and urine output, and delay the need for blood transfusions. this will be the first study to look at the effect that umbilical cord milking has on important measures of blood flow, which can predict bleeding in the head and subsequent developmental problems in very premature babies.

Eligibility criteria:
inclusion criteria: * infants \< 32 weeks gestation exclusion criteria: * obstetrician's refusal to participate * multiple gestations (if di-mo placentation) surrogate delivery * parental desire for cord blood banking * major congenital anomalies * severe maternal illness * placental abruption or previa * ruptured uterus at delivery, or hemoperitoneum

Keywords: superior vena cava flow umbilical cord milking hemodynamics systemic blood flow
study of s-1 plus lv for untreated metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this is a multicenter study designed to evaluate the response rate of s-1 plus leucovorin (1 week on and 1 week off) as first -line treatment for patients with metastatic colorectal cancer.


Eligibility criteria:
inclusion criteria: * histologically proved adenocarcinoma * unresectable and recurrent colorectal cancer * age20 ≤ at enrollment * performance status 0 or 1 (ecog) * no prior treatment (ex. radiation therapy, chemotherapy, hormonal therapy) to advanced disease. patients who received adjuvant chemotherapy more than 180 days before enrollment can be allowed but those who received s-1 containing treatment shall be excluded * adequate hematologic, hepatic and renal functions * at least one measurable lesion by recist criteria exclusion criteria: * serious drug hypersensitivity * pregnant or nursing * bleeding from gastrointestinal tract * diarrhea * simultaneously active double cancer * serious illness or medical condition * brain metastasis
postoperative dose of parathyroid hormone as a marker for the occurrence of hypoparathyroidism after total thyroidectomy

Conditions: Hypoparathyroidism

Summary: the main objective of this study is to establish an optimal threshold early parathormon (pth) assay in order to exclude hypoparathyroidism , that is to say to obtain a negative predictive value of hypoparathyroidism highest possible.


Eligibility criteria:
inclusion criteria: * patients consecutively operated on between february 1, 2012 and december 1, 2013 * total thyroidectomy +/- lymphadenectomy * respect of clinicobiological protocol presented above * the ( the ) patient ( e) was informed ( e) on the implementation of the study 's objectives, constraints and patient rights * the ( the ) patient ( e) is under ( e) at least 18 years exclusion criteria: * the ( the ) patient ( e) is under guardianship, curatorship or under guard saves justice * it is not possible to give to ( the ) patient ( e) informed information * history of cervical radiotherapy * previous history of dysfunction of the parathyroid glands * previous history of surgery of the parathyroid glands * a history of kidney failure or hepatocellular * history of osteomalacia or paget's disease * unhealed cancer antecedent * history of sarcoidosis
functional mri evaluation in pyeloureteral junction syndrome in children

Conditions: Stricture of Pelviureteric Juncture

Summary: pyelo-ureteral junction syndrome is the most common urological abnormality in children. functional mri has been evaluated several times, and had shown good correlation with scintigraphy, but tends to over estimate results. moreover, those studies included a small number of cases. its sensitivity to detect crossing polar vessel is limited. we aimed to evaluate, in patients between 0 and 1 year old, the correlation between mri and scintigraphy differential renal function. our secondary objectives are : evaluation of mri performances to detect polar vessel ; comparison of surgery times depending of mri only realisation or mri and scintigraphy realisation.


Eligibility criteria:
inclusion criteria: * children between 0 and 17 years old * followed for pyelo-ureteral junction syndrome exclusion criteria: * none

Keywords: pujs mri scintigraphy polar vessel
vasoactive intestinal peptide in copd

Conditions: COPD; Pulmonary Hypertension

Summary: this study, a new immunomodulatory therapy of copd with vasoactive intestinal peptide (vip) was evaluated. based on preliminary unpublished clinical and experimental results, the course of disease under vip treatment and the molecular mechanisms involved were assessed. 34 patients with severe copd were treated either with vip inhalation in addition to conventional therapy or inhalation of placebo plus conventional therapy for a period of 3 months. the trial was conducted as a double blind, comparative study with two parallel groups.

chronic obstructive bronchitis is a chronic inflammatory disease of the airways, which affects as many as 8% of individuals in industrialized nations. there is an increase in the number of woman and men suffering from copd. pulmonary hypertension and cor pulmonale are common sequelae of chronic airflow obstruction, but the precise mechanisms of increased vascular resistance are unclear. potential causes of pulmo-nary hypertension in copd include emphysematous destruction of the capillary bed, remodeling of pulmonary vessels and hypoxic pulmonary vasoconstriction. this proposal, a new immunomodulatory therapy of copd with vasoactive intestinal peptide (vip) was evaluated. based on preliminary unpublished clinical and experimental results, the course of disease under vip treatment and the molecular mechanisms involved were assessed. 34 patients with severe copd were treated either with vip inhalation in addition to conventional therapy or inhalation of placebo plus conventional therapy for a period of 3 months. the trial was conducted as a double blind, comparative study with two parallel groups. in the absence of acute infection or acute worsening of the disease due to other conditions, 2 transbronchial biopsies were collected before treatment, and after 3 months of treat¬ment for assessment of the regulation of a) the immune response, b) the extracellular matrix and c) the epithelial growth. this assessment will be performed in fully equipped and experienced laboratories at the university of vienna.

Eligibility criteria:
inclusion criteria: * confirmed moderate to severe copd with or without pulmonary hypertension * male and female patients. * aged 18 - 75 years. * written consent. * adequate contraception in female patients of childbearing age. * negative pregnancy test (four-weekly test repetition). exclusion criteria: * lack of consent * pregnancy (four-weekly tests) * lactation * presumed non-cooperativeness * patients outside the stipulated age range * myocardial infarction within the last 12 months * stroke within the last 12 months * malignant diseases in anamnesis * legal incapacity * parallel participation in a clinical trial * parallel participation in a clinical trial within the last 4 weeks

Keywords: copd vasoactive intestinal peptide lung function
impact of anthropometrics data and of physical activity level in closed kinetic chain upper extremity stability test

Conditions: Shoulder Pain

Summary: the purpose of this study is to evaluate impact of anthropometric criteria to ckcuest score.


Eligibility criteria:
inclusion criteria: * aged to 18 to 25 years * capacity to consent * who has signed the consent exclusion criteria: * fracture history or upper limb luxation * is not possible to do the test because of pain * pregnant or nursing * refuse to participate * guardianship or protection of vulnerable adult

Keywords: ckcuest physical activity rehabilitation
chlorhexidine and garlic extract as potential topical virucidal therapeutic agents of non-genital warts

Conditions: Non-Genital Warts

Summary: aim(s) of the research: 1. evaluate the efficacy and safety of topical chlorhexidine (2%) solution vs garlic extract (15%) solution in treating non-genital warts. 2. explore possible relation between therapeutic response with demographic/clinical data. 3. identify patients satisfaction with each agent.

cutaneous warts or verruca are common, benign skin growths caused by human papilloma virus (hpv). there are several therapeutic modalities for warts: include destructive agents (keratolytics, cryotherapy, curettage and cautery, laser, photodynamic therapy), antimitotic agents (podophyllin, bleomycin, retinoids), immune stimulants (topical sensitizers, cimetidine), and topical virucidal agents (formaldehyde, glutaraldehyde) unfortunately, no single treatment is satisfactory for all patients. chlorhexidine gluconate(chx) is a gluconate salt with a broad-spectrum antiseptic action against gram-positive, gram-negative bacteria, aerobes, facultative anaerobes, and fungi such action is mediated through increasing the permeability of the cell walls of microbes, causing their lysis. additionally, evidence indicates an in vitro effect against many viruses such as influenza a, parainfluenza, herpes virus 1, cytomegalovirus, hepatitis b, hiv and sars-cov-2. it was hypothesized that the biophysiological mechanisms for the virucidal effect of chx may be exerted through lysis of viral envelope, deterioration of nucleotide carbon chains, and inactivation and/or blocking of viral proteins. garlic (allium sativum) is one of the most widely used medicinal plants with high therapeutic effects. clinical effectiveness of oral and topical garlic extract may be attributed to its antimicrobial, antioxidant, anti-inflammatory, anticancer and aging prevention effects. however, the mechanisms of these actions are not clearly known. in vitro studies on garlic showed that garlic may enhance natural killer (nk) cells, which are an important part of the immune system in fighting cancers, viruses and certain bacteria. previous studies showed garlic extract was effective on complete resolution of cutaneous wart. chlorhexidine has not been used for treatment of warts in previous studies so we decided to explore its efficacy in treatment of warts.

Eligibility criteria:
inclusion criteria: * patients with the clinical diagnosis of common or plantar warts. exclusion criteria: * pregnancy and lactation. * chronic systemic diseases such as chronic renal failure, hepatic insufficiency, and cardiovascular disorders. * patients with inflamed lesions * use of systemic or topical treatments during the last month before enrollment. * individuals with history of allergic reactions to garlic or chlorhexidine * patient with generalized dermatitis or allergic skin disorders
physical activity after cardiac arrest; a sub-study in the target temperature management trial 2

Conditions: Heart Arrest, Out-Of-Hospital; Physical Activity

Summary: the target temperature management trial 2 (ttm2) is an international multi-center study, that randomize patients with ohca of a presumed cardiac or unknown cause to target temperature management at 33°c or normothermia but avoiding fever (37.8°c) for the first 24 hours after the ohca. the ttm2 study (clinicaltrials.gov identifier nct02908308) includes a detailed follow-up of functional outcome, health-related quality of life and neurocognitive function at 6 and 24 months post-arrest. this protocol describes a sub-study within the ttm2 trial that specifically focus on physical activity among the ohca survivors.

the primary aim of this study is to investigate whether ohca-survivors have lower levels of self-reported physical activity compared to a non-cardiac arrest (ca) control group who had acute myocardial infarction (mi). additional aims are to explore potential predictors of physical inactivity (older age, female gender, problems with general physical function, global cognition, mental processing speed/attention, anxiety symptoms, depression symptoms, kinesiophobia, fatigue), and to investigate the relationship between self-reported and objectively measured physical activity among ohca-survivors.

Eligibility criteria:
inclusion criteria: * the ttm2 main trial includes adult, unconscious patients with sustained return of spontaneous circulation after cardiac arrest of a presumed cardiac origin. the aim is to include 100-150 ohca-survivors to the sub-study. exclusion criteria: * an exclusion criterion for the ttm2 main trial is an unwitnessed cardiac arrest with initial rhythm asystole, temperature at admission \<30°c, on extracorporeal membrane oxygenation (ecmo) prior to return of spontaneous circulation (rosc), obvious or suspected pregnancy, intracranial bleeding and/or severe chronic obstructive pulmonary disease (copd) on home oxygen. an additional exclusion criterion for the sub-study is the inability to speak the local language well enough to complete the test without an interpreter. patients with major cognitive impairment, patients sitting in a wheel chair, clinical frailty score 8 or 9 (very severely frail or terminally ill), active drug abuse and when a face-to face follow-up is not possible will also be excluded.

Keywords: physical training kinesiophobia